Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine.

The aim of the present study was to compare the contribution of the labelled tracers [C-11]methionine (Met) and [F-18]-fluorodeoxyglucose (FDG) in positron emission tomography (PET)-guided stereotactic biopsy of non resectable brain lesions. Twenty-five patients underwent combined Met-PET-, FDG-PET- and computerized tomography (CT)- or magnetic resonance (MR)-guided stereotactic biopsy according to a previously described technique for stereotactic FDG-PET. Met-PET and FDG-PET images were analyzed to determine which tracer offers the best information to guide at least one stereotactic biopsy trajectory. Histological diagnosis was obtained in all patients (23 tumours and 2 non-tumorous lesions). All tumours had an area of abnormal Met uptake and were biopsied under PET-guidance. FDG uptake in the tumour was higher than in the grey matter and was used for target selection in 12 of 23 tumours. Eleven of them were located in the basal ganglia or the brainstem. Met was used for target selection in 11 of 23 tumours where there was no FDG uptake or where FDG uptake was equivalent to that of the grey matter. Ten of them were located in the cortex. Two nontumoral lesions had no Met uptake and were biopsied under CT- or MR-guidance only. Forty-three out of 53 stereotactic trajectories obtained in these 25 patients were based on PET-defined targets and had an area of abnormal Met uptake. These trajectories always yielded a diagnosis of tumour. Moreover, all tumorous trajectories had an area of abnormal Met uptake. Finally, all non-diagnostic trajectories (n = 4) were CT/MR-defined because there was no area of abnormal Met uptake. These results suggest that patients who can benefit the most from Met-PET guidance could be selected pre-operatively. In conclusion, this work shows that Met is a good alternative to FDG for target selection in PET-guided stereotactic brain biopsy.

[1]  M. Bergström,et al.  Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. , 1985, Journal of computer assisted tomography.

[2]  G Di Chiro,et al.  Prediction of survival in glioma patients by means of positron emission tomography. , 1985, Journal of neurosurgery.

[3]  H von Holst,et al.  PET Study of Methionine Accumulation in Glioma and Normal Brain Tissue: Competition with Branched Chain Amino Acids , 1987, Journal of computer assisted tomography.

[4]  G. Chiro.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .

[5]  B A Kall,et al.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.

[6]  M. Bergström,et al.  Positron Emission Tomography with 11C-Methionine and Computed Tomography of Intracranial Tumours Compared with Histopathologic Examination of Multiple Biopsies , 1987, Acta radiologica.

[7]  Abass Alavi,et al.  Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.

[8]  Derlon Jm,et al.  [11C]L-methionine uptake in gliomas. , 1989 .

[9]  Maurice M. Smith,et al.  Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. , 1989, Neurosurgery.

[10]  B. G. Rule,et al.  Computed tomography in the diagnosis of malignant brain tumours: do all patients require biopsy? , 1989, Journal of neurology, neurosurgery, and psychiatry.

[11]  A. Friedman,et al.  Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography , 1991, Annals of neurology.

[12]  J M Hoffman,et al.  Clinical application of PET for the evaluation of brain tumors. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A. Friedman,et al.  Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas , 1991, Neurology.

[14]  M Kowada,et al.  Innovative approach in the diagnosis of gliomatosis cerebri using carbon-11-L-methionine positron emission tomography. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  P. Black,et al.  MEDICAL PROGRESS : BRAIN TUMORS (SECOND OF TWO PARTS) , 1991 .

[16]  Positron emission tomography-guided stereotactic brain biopsy. , 1992 .

[17]  R. Kiss,et al.  Assessment of nuclear size, nuclear DNA content and proliferation index in stereotaxic biopsies from brain tumours , 1993, Neuropathology and applied neurobiology.

[18]  F Shishido,et al.  Cerebral glioma: evaluation with methionine PET. , 1993, Radiology.

[19]  A. Luxen,et al.  Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. , 1995, Journal of neurosurgery.

[20]  C Decaestecker,et al.  Stereotactic biopsies from astrocytic tumors. Diagnostic information contributed by the quantitative chromatin pattern description. , 1995, Analytical and quantitative cytology and histology.

[21]  S. Goldman,et al.  Regional glucose metabolism and histopathology of gliomas: A study based on positron emission tomography‐guided stereotactic biopsy , 1996, Cancer.

[22]  S. Goldman,et al.  Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.